Cargando…
PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas
BACKGROUND: Prolactinoma is the most common type of pituitary tumors, and its resultant tumor occupying and hormone disturbance greatly damage the health of patients. In this study, we investigated a protein kinase-PDZ Binding Kinase (PBK)/T-LAK Cell-Originated Protein Kinase (TOPK) as a candidate p...
Autores principales: | Zhu, Kejing, Cheng, Xueting, Wang, Shuman, Zhang, Hong, Zhang, Yu, Wang, Xiong, Chen, Yonggang, Wu, Jinhu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8815076/ https://www.ncbi.nlm.nih.gov/pubmed/35126305 http://dx.doi.org/10.3389/fendo.2021.706909 |
Ejemplares similares
-
PBK/TOPK Expression Predicts Prognosis in Oral Cancer
por: Chang, Chin-Fang, et al.
Publicado: (2016) -
PBK/TOPK: A Therapeutic Target Worthy of Attention
por: Han, Ziping, et al.
Publicado: (2021) -
The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas
por: Wang, Shuman, et al.
Publicado: (2021) -
PBK/TOPK: An Effective Drug Target with Diverse Therapeutic Potential
por: Huang, Hai, et al.
Publicado: (2021) -
PBK/TOPK mediates geranylgeranylation signaling for breast cancer cell proliferation
por: Dou, Xiaoyan, et al.
Publicado: (2015)